All patients had the typical CD19 + /CD5 + /CD23 + phenotype. PBMCs were isolated by Ficoll-Hypaque gradient centrifugation and B-cells were purified by negative selection, using a CLL B-cell isolation kit (Macs Miltenyi Biotec, Leiden, The Netherlands). The CLL B-cells were cultured at a density of 4×10 6 cells/500 µl in RPMI 1640 (Lonza, Verviers, Belgium) with 10% fetal bovine serum filtered through a 0.2-μm filter. These samples were cultured for 24 h before functional studies and RNA extraction.
Monitoring of BM-MSC EV uptake by CLL B-cells
EVs from BM-MSCs were labeled with PKH67, a green fluorescent dye that labels lipid membranes (Sigma Aldrich, Missouri, USA). EVs were incubated in 2 μl of PKH67 (2 μM) for 5 minutes, followed by incubation in 1% bovine serum albumin (BSA) at room temperature to stop the reaction and washed with PBS at 150 000 × g to remove excess dye. For the negative control, PBS was incubated with PKH67 and treated with the same procedure. A MACSQuant Analyzer (Miltenyi Biotec) was used to monitor the uptake of EVs by CLL B-target cells. CLL B-cells were cultured with BM-MSC EVs previously labeled with the fluorescent dye PKH67 for 10 minutes, 1 h, 3 h or 24 h. Internalization of EVs was detected within 10 minutes by flow cytometry, and an increased internalization of PKH67 positive EVs was detected with time, as shown with the Mean Fluorescence Intensity (MFI) in the Figure 1 . To exclude false positive results due to dye contamination, we added PKH67-labeled PBS to samples. No "dye contamination fluorescence" was detected on samples, confirming that the washing steps in our protocol were efficient. We used flow cytometry to evaluate antigen expression in CLL Bcells after EV integration, and we observed the increased expression of CD63 (microvesicle marker), supporting the antigen transfer theory (data not shown).
Migration assay
Briefly, 10 6 CLL B-cells were resuspended in 200 µl of RPMI medium (without serum) and plated in the upper chamber of a 6.6-mm diameter Transwell culture insert in bare polycarbonate with a 5-µm pore size (Corning Incorporated, NY, USA). The lower chamber of each well contained 500 µl of RPMI medium with or without SDF-1α (stromal cell-derived factor 1α, a CXC chemokine, highly produced by BM-MSCs, that induces CLL cell migration) (100 ng/mL) (R&D Systems, Minneapolis, MN, USA). To evaluate the effect of EVs on cell migration, CLL B-cells were pre-incubated with 2 µg of BM-MSC EVs or with RPMI alone as a negative control for 4 h. This time of pre-incubation (4h) was chosen to allow the complete integration of EVs in CLL B-cells and the initiation of physiologic effect. After 4 hours of culture, cells were recovered from the lower chamber and concentrated by centrifugation. The absolute number of cells was then determined as follows: 100 µl of the cell suspension was counted with a MACSQuant Analyzer (Miltenyi Biotec) using the absolute volumetric cell counting function. The migration index was calculated as the number of cells transmigrating in the presence of SDF-1α divided by the number of transmigrating cells in the absence of SDF-1α and EVs. CLL B-cells were also preincubated during 1h with the CXCR4 antagonist AMD3100 (5µg/ml) and pertussis toxin (200ng/ml), a G-protein inhibitor, in order to evaluate action mechanism of EVs. The migration ratio represents the number of migrating cells in each condition divided by the spontaneous migrating cells (in absence of EVs).
Measure of genes involved in apoptosis
Myeloid cell leukemia 1 (Mcl-1) intracellular expression was determined by flow cytometry using primary unconjugated antibody with a secondary antibody coupled to FITC (Immunoglobulin swine F(ab') 2 / DAKO, Denmark) and cell lymphoma extra-large (BCL-XL), X-linked inhibitor apoptosis protein (XIAP), B-cell CLL/lymphoma 2 (BCL2) and BCL2-associated X protein (BAX) expression were investigated by qPCR (quantitative real-time PCR) with specific primers.
Drugs for chemosensitivity assay
Flavopiridol (Sigma-Aldrich, Bornem, Belgium) and fludarabine (FLUDARA; Schering AG, Berlin, Germany) were dissolved to make stock solutions in water at 1 µM and 100 µM, respectively. Bortezomib (VELCADE) (Millennium Pharmaceuticals, Cambridge, MA, USA) was dissolved in dimethyl sulfoxide at a concentration of 1 mM. Cladribine (2CdA) (Sigma-Aldrich) and methylprednisolone (Sigma-Aldrich) were dissolved in absolute ethanol. Ibrutinib, idelalisib (CAL-101) and venetoclax (ABT-199) (Selleckchem.com, Munich, Germany) were diluted in water at a concentration of 1mM for ibrutinib and idelalisib and 1µM for venetoclax. Stock solutions in DMSO were stored at -20°C. CLL B-cells were pre-incubated with 2 µg of BM-MSC EVs or with RPMI as a negative control for 4 h and placed into 24-well plates with drugs. Apoptosis was then evaluated after 24 h by Annexin-V/7AAD labeling as described in the main manuscript. The results were normalized to the negative control (cells without drug and EVs).
Gene expression profile and bioinformatic analysis
Gene expression profiles comparing CLL cells cultured with or without 5 µg of EVs were performed as previously described 2 . Total RNA was extracted from CLL B-cells cultured with or without 5 µg of EVs in a single step with TriPure Isolation Reagent (Roche Applied Science). Microarray analysis was performed using 120 ng of RNA with the Affymetrix GeneChip® Human Genome U133 Plus 2.0 Array (Affymetrix, High Wycombe, UK). Amplification, hybridization, and scanning were performed according to standard Affymetrix protocols as described previously 2 . The data discussed in this publication have been deposited in the NCBI Gene Expression Omnibus and are accessible through GEO Series accession number GSE82051
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82051). A comparative and explorative gene expression profile was determined for 6 samples. CLL B-cells were obtained from 3 different patients and were incubated with or without EVs for 24 h. We identified significant differences between sample groups using the BRB Array Tools (Biometric Research Branch, National Cancer Institute, Bethesda, MA, USA). Only probe sets defined as present by the Affymetrix algorithm in at least 80% (5/6) of the cases were considered for further analysis. We performed two-sample paired t tests with a random variance model on the two groups, with or without EVs, for each gene. The false discovery rate (FDR) correction was applied but not used because of the low number of paired samples (n=3). However, genes of interest were further validated on a larger number of patient samples by real-time PCR. Using BRB gene set expression comparison tools, overrepresentation of gene ontology (GO) categories were investigated by the least squares (LS) permutation test. The ''SuperExactTest'' was applied to assess the statistical significance of intersections between different gene signatures. This test provides a p value characterizing the statistical difference between the expected and the obtained overlaps as described by
Wang and colleagues 3 . To calculate this parameter, we used 12500 genes as total number of genes (obtained by removing the probesets considered as "absent" by the detection call algorithm in 80% of samples and by reducing this number to only one probeset per gene (the most expressed)).
Flow cytometry analysis
All harvested cells were analyzed on a MACSQuant Analyzer flow cytometer (Miltenyi Biotec). To establish the phenotype of CLL B-cells and BM-MSCs, the cells were washed with PBS, resuspended in 100 μl and labeled with specific fluorochrome-labeled monoclonal antibodies for 15 minutes in the dark.
All antibodies are listed in the Online Supplementary Table S9 . Cells were washed with PBS, fixed with a 4 % formaldehyde solution and a minimum of 20 000 cells were acquired. Collected data from all experiments were analyzed using FCS 3.0 (De Novo analysis software, Los Angeles, CA, USA). BM-MSCs were characterized by the positive expression of CD105, CD73, CD90, CD146 and CD166 and were negative for CD45 as presented in the Online Supplementary Figure S1 . We compared the expression of these markers with the BM-MSCs obtained from healthy and CLL patients as presented in the Online Supplementary Table S10 . CLL B-cells were characterized by the typical CD5+, CD19+ and CD23+ phenotype.
Validation by Real-time PCR analysis (qPCR)
We used 12.5 ng of cDNA produced by standard reverse transcription in a qPCR reaction with power SYBR ® Green PCR Master Mix (Life Technologies, Merelbeke, Belgium) and 0.32 µM gene-specific forward and reverse primers (Life Technologies, Merelbeke, Belgium). Primer sequences are listed in the Online Supplementary Table S11 . Standard real-time PCR was performed on an ABI VIAA7 (Life Technologies). To ensure that all expression levels were comparable, the data were normalized to the cyclophilin A gene (PPIA) as an endogenous control and calibrated by subtracting 10 (chosen arbitrarily) from the ΔCt value. The comparative ΔΔCt method was then applied for data analysis, and fold changes were subsequently calculated (fold change = 2 -ΔΔCt ) as described by Van Damme et al 4 .
EV effect on CLL B-cell BCR activation
To . These prognostic factors were assessed as previously described 5 . 
Table S6: Comparison of microarray profiles between CLL B-cells activated by EVs from BM-MSC, by NLC culture, and CLL B-cells from lymph nodes (LN) and bone marrow (BM) -the 20 most increased genes.
We listed the 20 most differentially expressed genes in our microarray signatures compared with signature of CLL B-cells activated by NLC culture and with signature of CLL B-cells coming from LN and BM. We observed multiple common genes; between 5 and 50% of genes were similar. 
Table S7: Comparison of microarray profiles between CLL B-cells activated by EVs from BM-MSC, by NLC culture, and CLL B-cells from lymph nodes (LN) and bone marrow (BM) -the 20 most decreased genes.
We listed the 20 most differentially expressed decreased genes in our microarray signatures compared with signature of CLL B-cells activated by NLC culture and with signature of CLL B-cells coming from LN and BM. We observed multiple common genes; between 30 and 85% of genes were similar. Table S11 : Used primer sequences in the qPCR study. Forward and reverse primer sequences of genes studied in CLL B-cells by qPCR. Figure S1 : Characterization of BM-MSCs. BM-MSCs were characterized by flow cytometry, they expressed classical markers of MSCs (CD105, 73, 146, 90 and 166) and were negative for CD45. The fibroblast-like morphology was confirmed by optical microscopy.
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Figure S2: EV quantity effect on CLL B-cell apoptosis.
Apoptosis assay was performed on CLL B-cells that received two different quantities of EVs or nothing as a negative control. Low (Lo) EVs means between 0.25 and 1µg while High (Hi) EVs means more than 1µg for 4 million of cells. We observed a significant impact of higher quantity of EVs on CLL B cell apoptosis.
Figure S3: Expression of genes involved in apoptosis after EV integration in CLL B-cells.
We studied the expression of BCLXL, XIAP, BCL2 and BAX in CLL B-cells after EV integration. We noted an increased expression of BCLXL and XIAP mRNA by qPCR but no difference was observed for BCL2 and BAX. 
